AAUM (Average Assets Under Management) of ₹3,097.34 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 72.1% | 71.3% | ▼ -0.9% |
| Healthcare Services | 24.2% | 22.1% | ▼ -2.0% |
| Healthcare Equipment & Supplies | 2.2% | 2.4% | ▲ +0.2% |
| Retailing | 0.0% | 1.0% | ▲ +1.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 71.3% | 70.9% | ▼ -0.4% |
| Healthcare Services | 22.1% | 24.8% | ▲ +2.7% |
| Healthcare Equipment & Supplies | 2.4% | 2.2% | ▼ -0.2% |
| Retailing | 1.0% | 0.9% | ▼ -0.1% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Weight (Oct 2026) |
|---|---|---|---|
| 1 | Paras Healthcare Ltd. ₹85.72 Cr |
Healthcare Services | 2.34% |
| # | Stock | Sector | Last Weight (Sep 2026) |
|---|---|---|---|
| 1 | Cohance Lifesciences Limited ₹11.10 Cr |
Pharmaceuticals & Biotechnology | 0.32% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Dr. Reddy's Laboratories Limited ₹244.03 Cr |
Pharmaceuticals & Biotechnology | 3.19% | 6.66% | +3.47% |
| 2 | Apollo Hospitals Enterprise Limited ₹190.25 Cr |
Healthcare Services | 3.69% | 5.19% | +1.50% |
| 3 | Acutaas Chemicals Ltd ₹135.73 Cr |
Pharmaceuticals & Biotechnology | 3.18% | 3.70% | +0.52% |
| 4 | Rubicon Research Limited ₹98.78 Cr |
Pharmaceuticals & Biotechnology | 2.52% | 2.69% | +0.17% |
| 5 | Sai Life Sciences Limited ₹63.76 Cr |
Pharmaceuticals & Biotechnology | 1.58% | 1.74% | +0.16% |
| 6 | Alkem Laboratories Limited ₹173.98 Cr |
Pharmaceuticals & Biotechnology | 4.64% | 4.75% | +0.11% |
| 7 | Divi's Laboratories Limited ₹345.91 Cr |
Pharmaceuticals & Biotechnology | 9.39% | 9.44% | +0.05% |
| 8 | Zydus Lifesciences Limited ₹68.37 Cr |
Pharmaceuticals & Biotechnology | 1.82% | 1.86% | +0.04% |
| 9 | Symbiotec Pharmalab Limited ₹50.46 Cr |
Pharmaceuticals & Biotechnology | 1.36% | 1.38% | +0.02% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | IPCA Laboratories Limited ₹70.69 Cr |
Pharmaceuticals & Biotechnology | 2.98% | 1.93% | -1.05% |
| 2 | Gland Pharma Limited ₹38.57 Cr |
Pharmaceuticals & Biotechnology | 1.78% | 1.05% | -0.73% |
| 3 | Sun Pharmaceutical Industries Limited ₹283.56 Cr |
Pharmaceuticals & Biotechnology | 8.28% | 7.74% | -0.54% |
| 4 | Shilpa Medicare Ltd ₹107.10 Cr |
Pharmaceuticals & Biotechnology | 3.23% | 2.92% | -0.31% |
| 5 | Torrent Pharmaceuticals Limited ₹122.94 Cr |
Pharmaceuticals & Biotechnology | 3.65% | 3.35% | -0.30% |
| 6 | Neuland Laboratories Limited ₹108.38 Cr |
Pharmaceuticals & Biotechnology | 3.24% | 2.96% | -0.28% |
| 7 | Anthem Biosciences Limited ₹107.05 Cr |
Pharmaceuticals & Biotechnology | 3.17% | 2.92% | -0.25% |
| 8 | Wockhardt Limited ₹53.85 Cr |
Pharmaceuticals & Biotechnology | 1.71% | 1.47% | -0.24% |
| 9 | Krishna Institute Of Medical Sciences Limited ₹69.10 Cr |
Healthcare Services | 2.10% | 1.89% | -0.21% |
| 10 | Lupin Limited ₹122.97 Cr |
Pharmaceuticals & Biotechnology | 3.55% | 3.35% | -0.20% |
38 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹345.91 Cr |
Pharmaceuticals & Biotechnology |
9.44%
|
|
| 2 |
₹283.56 Cr |
Pharmaceuticals & Biotechnology |
7.74%
|
|
| 3 |
₹244.03 Cr |
Pharmaceuticals & Biotechnology |
6.66%
|
|
| 4 |
₹190.25 Cr |
Healthcare Services |
5.19%
|
|
| 5 |
₹173.98 Cr |
Pharmaceuticals & Biotechnology |
4.75%
|
|
| 6 |
₹148.93 Cr |
Pharmaceuticals & Biotechnology |
4.06%
|
|
| 7 |
₹135.73 Cr |
Pharmaceuticals & Biotechnology |
3.70%
|
|
| 8 |
₹126.13 Cr |
Healthcare Services |
3.44%
|
|
| 9 |
₹123.37 Cr |
Healthcare Services |
3.37%
|
|
| 10 |
₹122.94 Cr |
Pharmaceuticals & Biotechnology |
3.35%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.